Resources Repository
-
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Cost-Effectiveness Analysis | State-Transition | Health/Medicine | North America | Infectious Diseases | Test Performance | Microsimulation | Chronic Disease/Risk | Health Systems | Economics/Finance | Global -
ArticlePublication 2022Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 …
In the wake of the COVID-19 pandemic's significant educational disruptions, the U.S. government allocated $10 billion in March 2021 for testing in schools. The study aimed to analyze the costs and benefits of different COVID-19 testing strategies, particularly focusing on full-time, in-person elementary and middle school education. Utilizing an updated agent-based network model, the study simulated transmission scenarios in schools, considering various testing strategies ranging from diagnostic testing (test-to-stay) to reduce symptom-based isolations, routine screening…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Test Performance | Mathematical Models | Clinical Care | Science/Technology -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
State-Transition | Health/Medicine | North America | Infectious Diseases | Mathematical Models | Benefit-Cost Analysis | Policy/Regulation | Business/Industry | Economics/Finance | Government/Law -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Global -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Microsimulation | Decision Analysis | Chronic Disease/Risk -
ArticlePublication 2017Predicting Carer Health Effects for Use in Economic Evaluation
Illnesses and interventions can affect the health status of family carers in addition to patients. …
Illnesses and interventions can affect the health status of family carers in addition to patients. However economic evaluation studies rarely incorporate data on health status of carers. In order to investigate whether changes in carer health status could be ‘predicted’ from the health data of those they provide care to, as a means of incorporating carer outcomes in economic evaluation, the authors used regression models to analyse changes in carers’ health status. They derive predictive algorithms based on…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Preferences/Values | Health Outcomes | Europe -
ArticlePublication 2016Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and …
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and treatment in U.S. prisons on the broader HCV epidemic. Employing an agent-based microsimulation model of HCV transmission and disease progression, data from published literature inform the analysis. The target populations include individuals in U.S. prisons and the general community over a 30-year timeframe, adopting a societal perspective. Interventions encompass risk-based and universal opt-out HCV screening in prisons, followed by treatment…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Microsimulation | Chronic Disease/Risk -
ArticlePublication 2015Clinical Role and Cost-Effectiveness of Long-Acting ART
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with …
Long-acting antiretroviral therapy (LA-ART) could potentially improve outcomes in particular for those HIV-infected individuals with poor daily ART adherence. In this study the clinical role and cost-effectiveness of 3 long-acting ART strategies (LA-ART for patients with multiple ART failures; second-line LA-ART for those failing first-line therapy; and first-line LA-ART for ART-naive patients) are compared to daily oral ART using a microsimulation model. The findings of this study showed that LA-ART could improve survival of…
Cost-Effectiveness Analysis | Health/Medicine | North America | Infectious Diseases | Microsimulation